Antibody Engineering: Optimizing the Delivery Vehicle

Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer

Volumn , Issue , 2010, Pages 1-38

  Milenic, Diane E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody engineering delivery vehicle optimizing; Hypervariable (HV) domain region peptides targeting and binding to tumor associated antigens; Selective high affinity ligands

Indexed keywords

EID: 84878184607     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470613214.ch1     Document Type: Chapter

References (177)

1. 131-carrying antibodies to fibrin. Cancer Res 1960;20:1488-1494.
2. Pressman D. The development and use of radiolabeled antitumor antibodies. Cancer Res 1980;40:2960-2964.
3. Hiramoto R, Yagi Y, Pressman D. In vivo fixation of antibodies in the adrenal. Proc Soc Exp Biol Med 1958;98:870-874.
4. McCardle RJ, Harper PV, Spar IL, Bale WF, Andros G, Jiminez F. Studies with iodine-131-labeled antibody to human fibrinogen for diagnosis and therapy of tumors. J Nucl Med 1966;7:837-847.
5. Ehrlich P, Herta C, Shigas K. Ueber einige verwendungen der naphtochinosuflsaure. Ztschr f Physiol Chem 1904;61:379-392.
6. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-497.
7. Knox SJ, Meredith RF. Clinical radioimmunotherapy. Semin Radiat Oncol 2000;10:73-93.
8. Jurcic JG, Scheinberg DA. Radioimmunotherapy of hematological cancer: problems and progress. Clin Cancer Res 1995;1:1439-1446.
9. Schlom J. Monoclonal antibodies: they're more and less than you think. In: Broder S, editor. Molecular Foundations of Oncology.Williams andWilkins, Baltimore, MD, 1990.
10. Reichert JM,Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug Discov Today 2008;13:30-37.
11. Witzig TE. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma. Semin Oncol 2000;27:74-78.
12. Vose JM. Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist 2004;9:160-172.
13. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994;15:42-52.
14. Tamura M, Milenic DE, Iwahashi M, Padlan E, Schlom J, Kashmiri SV. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J Immunol 2000;164:1432-1441.
15. Blanco I,Kawatsu R, Harrison K, et al. Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. J Clin Immunol 1997;17:96-106.
16. Milenic DE, Esteban JM, Colcher D. Comparison of methods for the generation of immunoreactive fragments of a monoclonal antibody (B72.3) reactive with human carcinomas. J Immunol Methods 1989;120:71-83.
17. Parham P, Androlewicz MJ, Brodsky FM, Holmes NJ, Ways JP. Monoclonal antibodies: purification, fragmentation and application to structural and functional studies of class I MHC antigens. J Immunol Methods 1982;53:133-173.
18. Waller M, Curry N, Mallory J. Immunochemical and serological studies of enzymatically fractionated human IgG globulins. I. Hydrolysis with pepsin, papain, ficin and bromelin. Immunochemistry 1968;5:577-583.
19. 2 anticarcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer 1999;85:1828-1842.
20. 2 antibodies. Br J Cancer 1994;70:521-525.
21. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-3408.
22. Milenic DE, Yokota T, Filpula DR, et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1991;51:6363-6371.
23. Carrasquillo JA, Krohn KA, Beaumier P, et al. Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep 1984; 68:317-328.
24. Schott ME, Milenic DE, Yokota T, et al. Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules. Cancer Res 1992;52:6413-6417.
25. Yokota T, Milenic DE, Whitlow M, Wood JF, Hubert SL, Schlom J. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res 1993;53:3776-3783.
26. Behr TM, Sharkey RM, Juweid ME, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995;55:3825-3834.
27. 177Lu]alpha-[2-(4-aminophenyl) ethyl]-1,4,7,10-tetraaza-cyclodecane-1,4,7,10-tetraacetic acid-CC49 Fab radioimmunoconjugate. Cancer Res 1995;55:5288-5295.
28. Morrison S, Schlom J. Recombinant chimeric monoclonal antibodies. In: DeVita V, Rosenberg S, editors. Important Advances in Oncology. JB Lippincott, Philadelphia, PA, 1990, pp. 3-18.
29. Hiatt A, Cafferkey R, Bowdish K. Production of antibodies in transgenic plants. Nature 1989;342:76-78.
30. LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989;86:4220-4224.
31. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007;96:417-423.
32. Litvinov SV, Bakker HA, Gourevitch MM, Velders MP, Warnaar SO. Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion. Cell Adhes Commun 1994;2:417-428.
33. Meredith RF, Khazaeli MB, Grizzle WE, et al. Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer. Hum Antibodies Hybridomas 1993;4:190-197.
34. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-2195.
35. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementaritydetermining regions in a human antibody with those from a mouse. Nature 1986;321:522-525.
36. Padlan EA. Anatomy of the antibody molecule. Mol Immunol 1994;31:169-217.
37. Amit AG, Mariuzza RA, Phillips SE, Poljak RJ. Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution. Science 1986;233:747-753.
38. Kashmiri SV, De Pascalis R, Gonzales NR. Developing a minimally immunogenic humanized antibody by SDR grafting. Methods Mol Biol 2004;248:361-376.
39. Kashmiri SV, Shu L, Padlan EA, Milenic DE, Schlom J, Hand PH. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma 1995;14:461-473.
40. Winter G, Harris WJ. Humanized antibodies. Immunol Today 1993;14:243-246.
41. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323-327.
42. Caron PC, Schwartz MA, Co MS, et al. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia. Cancer 1994;73:1049-1056.
43. Sharkey RM, Juweid M, Shevitz J, et al. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res 1995;55:5935s-5945s.
44. Kramer EL, Liebes L, Wasserheit C, et al. Initial clinical evaluation of radiolabeled MXDTPA humanized BrE-3 antibody in patients with advanced breast cancer. Clin Cancer Res 1998;4:1679-1688.
45. Caron PC, Jurcic JG, Scott AM, et al.Aphase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 1994;83:1760-1768.
46. Schneider WP, Glaser SM, Kondas JA, Hakimi J. The anti-idiotypic response by cynomolgus monkeys to humanized anti-Tac is primarily directed to complementarity-determining regions H1, H2, and L3. J Immunol 1993;150:3086-3090.
47. Singer II, Kawka DW, DeMartino JA, et al. Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of humanV-region framework sequences. J Immunol 1993;150:2844-2857.
48. Stephens S, Emtage S, Vetterlein O, et al. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 1995;85:668-674.
49. Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 2003;5:172-179.
50. Nanus DM, Milowsky MI, Kostakoglu L, et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 2003;170: S84-S88; discussion S88-S89.
51. Smith-Jones PM. Radioimmunotherapy of prostate cancer. Q J Nucl Med Mol Imaging 2004;48:297-304.
52. Mulligan T, Carrasquillo JA, Chung Y, et al. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1995;1:1447-1454.
53. Iwahashi M, Milenic DE, Padlan EA, Bei R, Schlom J, Kashmiri SV. CDRsubstitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity. Mol Immunol 1999;36:1079-1091.
54. Padlan EA, Abergel C, Tipper JP. Identification of specificity-determining residues in antibodies. FASEB J 1995;9:133-139.
55. Kashmiri SV, Iwahashi M, Tamura M, Padlan EA, Milenic DE, Schlom J. Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49. Crit Rev Oncol Hematol 2001;38:3-16.
56. De Pascalis R, Gonzales NR, Padlan EA, et al. In vitro affinity maturation of a specificitydetermining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants. ClinCancerRes 2003;9:5521-5531.
57. De Pascalis R, Iwahashi M, Tamura M, et al. Grafting of "abbreviated" complementaritydetermining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. J Immunol 2002;169:3076-3084.
58. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969;13:1-110.
59. Shuke N, Steis R, McCabe R. Pharmacokinetics of two human IgM monoclonal antibodies (16.88 and 28A32). J Nucl Med 1989;30:909.
60. Cole SP, Vreeken EH, Roder JC. Antibody production by human X human hybridomas in serum-free medium. J Immunol Methods 1985;78:271-278.
61. Green LL, Hardy MC, Maynard-Currie CE, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 1994;7:13-21.
62. Lonberg N, Taylor LD, Harding FA, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994;368:856-859.
63. Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005; 23:1117-1125.
64. Tomizuka K, Shinohara T, Yoshida H, et al. Doubletrans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies. Proc Natl Acad Sci USA 2000;97:722-727.
65. McCafferty J, Griffiths AD,Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990;348:552-554.
66. Rajpal A, Beyaz N, Haber L, et al. A general method for greatly improving the affinity of antibodies by using combinatorial libraries. Proc Natl Acad Sci USA 2005; 102:8466-8471.
67. Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol 2008.
68. Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004;58:984-990.
69. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004;22:3003-3015.
70. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993;363:446-448.
71. Dumoulin M, Conrath K, Van Meirhaeghe A, et al. Single-domain antibody fragments with high conformational stability. Protein Sci 2002;11:500-515.
72. Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther 2005;5:111-124.
73. Joosten V, Lokman C, Van Den Hondel CA, Punt PJ. The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. Microb Cell Fact 2003;2:1.
74. 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/ micro-CT. J Nucl Med 2008;49:788-795.
75. Cortez-Retamozo V, Lauwereys M, Hassanzadeh GhG, et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 2002;98:456-462.
76. Gillies SD, Wesolowski JS. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities. Hum Antibodies Hybridomas 1990;1:47-54.
77. Dorai H, Mueller BM, Reisfeld RA, Gillies SD. Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function. Hybridoma 1991;10:211-217.
78. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibodydependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 1990; 144:1382-1386.
79. H2 domain-deleted recombinant immunoglobulin. Int J Cancer 1993;53:97-103.
80. Slavin-Chiorini DC, Kashmiri SV, Lee HS, et al. A CDR-grafted (humanized) domaindeleted antitumor antibody. Cancer Biother Radiopharm 1997;12:305-316.
81. Slavin-Chiorini DC, Kashmiri SV, Schlom J, et al. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res 1995;55:5957s-5967s.
82. 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother Radiopharm 2004;19:135-147.
83. H2 region. Cancer Biother Radiopharm 2005;20:502-513.
84. Forero A, Meredith RF, Khazaeli MB, et al. A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother Radiopharm 2003;18:751-759.
85. H2) in recurrent and metastatic colorectal cancer patients. Cancer Biother Radiopharm 2005;20:16-26.
86. H2 domain-deleted antibodies. J Biol Chem 2005;280:41494-41503.
87. Sivolapenko GB, Douli V, Pectasides D, et al. Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody. Lancet 1995;346:1662-1666.
88. Williams WV, Kieber-Emmons T, VonFeldt J, Greene MI, Weiner DB. Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity. J Biol Chem 1991;266:5182-5190.
89. Bird RE, Hardman KD, Jacobson JW, et al. Single-chain antigen-binding proteins. Science 1988;242:423-426.
90. Skerra A, Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 1988;240:1038-1041.
91. Azuma T, Hamaguchi K, Migita S. Interactions between immunoglobulin polypeptide chains. J Biochem 1974;76:685-693.
92. Glockshuber R, Malia M, Pfitzinger I, Pluckthun A. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 1990;29:1362-1367.
93. L. J Immunol 1982;129:660-664.
94. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989;341:544-546.
95. Huston JS, Levinson D, Mudgett-Hunter M, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988;85:5879-5883.
96. Desplancq D, King DJ, Lawson AD, Mountain A. Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3. Protein Eng 1994; 7:1027-1033.
97. Power BE, Doughty L, Shapira DR, et al. Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody. Protein Sci 2003;12:734-747.
98. Wu AM. Engineering multivalent antibody fragments for in vivo targeting. Methods Mol Biol 2004;248:209-225.
99. Colcher D, Bird R, Roselli M, et al. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 1990;82:1191-1197.
100. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998;25:1341-1351.
101. Milenic DE, Brechbiel MW. Targeting of radio-isotopes for cancer therapy. Cancer Biol Ther 2004;3:361-370.
102. Wu AM, ChenW, Raubitschek A, et al. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology 1996;2:21-36.
103. Adams GP, Schier R, Marshall K, et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 1998;58:485-490.
104. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001;61:4750-4755.
105. Larson SM, El-Shirbiny AM, Divgi CR, et al. Single chain antigen binding protein (sFv CC49): first human studies in colorectal carcinoma metastatic to liver. Cancer 1997;80:2458-2468.
106. Begent RH, Verhaar MJ, Chester KA, et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 1996;2:979-984.
107. Mayer A, Tsiompanou E, O'Malley D, et al. Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin Cancer Res 2000;6:1711-1719.
108. Almog O, Benhar I, Vasmatzis G, et al. Crystal structure of the disulfide-stabilized Fv fragment of anticancer antibody B1: conformational influence of an engineered disulfide bond. Proteins 1998;31:128-138.
109. Bin Song K, Won M, Meares CF. Expression of recombinant Lym-1 single-chain Fv in Escherichia coli. Biotechnol Appl Biochem 1998;28 (Pt 2): 163-167.
110. Li Q, Hudson W, Wang D, Berven E, Uckun FM, Kersey JH. Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy. Cancer Immunol Immunother 1998;47:121-130.
111. Rodrigues ML, Presta LG, Kotts CE, et al. Development of a humanized disulfidestabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res 1995;55:63-70.
112. Webber KO, Kreitman RJ, Pastan I. Rapid and specific uptake of anti-Tac disulfidestabilized Fv by interleukin-2 receptor-bearing tumors. Cancer Res 1995;55:318-323.
113. RajagopalV, Pastan I, Kreitman RJ. Aform of anti-Tac(Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs. Protein Eng 1997;10:1453-1459.
114. Kobayashi H, Han ES, Kim IS, et al. Similarities in the biodistribution of iodine-labeled anti-Tac single-chain disulfide-stabilized Fv fragment and anti-Tac disulfide-stabilized Fv fragment. Nucl Med Biol 1998;25:387-393.
115. Holliger P, Prospero T, Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993;90:6444-6448.
116. Whitlow M, Filpula D, Rollence ML, Feng SL, Wood JF. Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv. Protein Eng 1994;7:1017-1026.
117. Yazaki PJ, Wu AM, Tsai SW, et al. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84. 66 minibody: comparison to radioiodinated fragments. Bioconjug Chem 2001;12:220-228.
118. Adams GP, Schier R, McCall AM, et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998;77:1405-1412.
119. BeresfordGW, PavlinkovaG, Booth BJ, Batra SK, Colcher D. Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody. Int J Cancer 1999;81:911-917.
120. Denton G, Brady K, Lo BK, et al. Production and characterization of an anti-(MUC1 mucin) recombinant diabody. Cancer Immunol Immunother 1999;48:29-38.
121. Adams GP, Shaller CC, Chappell LL, et al. Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl Med Biol 2000;27:339-346.
122. Robinson MK, Shaller C, Garmestani K, et al. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res 2008;14:875-882.
123. Adams GP, Shaller CC, Dadachova E, et al. A single treatment of yttrium-90-labeled CHX-A00-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res 2004;64:6200-6206.
124. Whitlow M, Bell BA, Feng SL, et al. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng 1993;6:989-995.
125. Kostelny SA, Cole MS, Tso JY. Formation of a bispecific antibody by the use of leucine zippers. J Immunol 1992;148:1547-1553.
126. Pack P, Pluckthun A. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry 1992;31:1579-1584.
127. H3 domains for heavy chain heterodimerization. Protein Eng 1996;9:617-621.
128. Pavlinkova G, Beresford G, Booth BJ, Batra SK, Colcher D. Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics, and biodistribution analysis. Nucl Med Biol 1999;26:27-34.
129. Goel A, Colcher D, Baranowska-Kortylewicz J, et al. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res 2000;60:6964-6971.
130. Wittel UA, Jain M, Goel A, Chauhan SC, Colcher D, Batra SK. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs. Nucl Med Biol 2005;32:157-164.
131. 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Eur J Nucl Med Mol Imaging 2005;32:264-273.
132. Adams GP, McCartney JE, Tai MS, et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 1993;53:4026-4034.
133. Adams GP, Tai MS, McCartney JE, et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 2006;12:1599-1605.
134. H3) which exhibits rapid, highlevel targeting of xenografts. Cancer Res 1996;56:3055-3061.
135. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003;44:1962-1969.
136. 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res 2004;10:5014-5021.
137. 2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 2004;17:315-323.
138. Rose LM, Deng CT, Scott SL, et al. Critical Lym-1 binding residues on polymorphic HLA-DR molecules. Mol Immunol 1999;36:789-797.
139. Shi XB, Gumerlock PH, Kroger L, DeNardo GL, DeNardo SJ. Efficient recombination of Lym-1 scFv gene using multiple doubly-restricted DNA fragments. Cancer Biother Radiopharm 1999;14:139-143.
140. Balhorn R, Hok S, Burke PA, et al. Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia. Clin Cancer Res 2007;13:5621s-5628s.
141. DeNardo GL, Natarajan A, Hok S, et al. Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma. J Nucl Med 2007;48:1338-1347.
142. Hok S, Natarajan A, Balhorn R, DeNardo SJ, DeNardo GL, Perkins J. Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia. Bioconjug Chem 2007;18:912-921.
143. West J, Perkins J, Hok S, et al. Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells. Cancer Biother Radiopharm 2006;21:645-654.
144. Nilsson B, Moks T, Jansson B, et al. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng 1987;1:107-113.
145. Wikman M, Steffen AC, Gunneriusson E, et al. Selection and characterization of HER2/ neu-binding affibody ligands. Protein Eng Des Sel 2004;17:455-462.
146. Steffen AC, Wikman M, Tolmachev V, et al. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm 2005;20:239-248.
147. Steffen AC, Orlova A, Wikman M, et al. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging 2006;33:631-638.
148. Orlova A, Tolmachev V, Pehrson R, et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 2007;67:2178-2186.
149. Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006;66:4339-4348.
150. 111/114mIn]CHX-A00-DTPA-ZHER2:342, an affibody ligand conjugate for targeting of HER2-expressing malignant tumors. Q J Nucl Med Mol Imaging 2007; 51:314-323.
151. Tolmachev V, Xu H,Wallberg H, et al. Evaluation of a maleimido derivative of CHX-A00 DTPA for site-specific labeling of affibody molecules. Bioconjug Chem 2008.
152. Rodewald R. pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol 1976;71:666-669.
153. Kim JK, Firan M, Radu CG, Kim CH, GhetieV,Ward ES. Mapping the site on human IgG for binding of the MHC class I-related receptor. FcRn. Eur J Immunol 1999; 29:2819-2825.
154. GhetieV, Popov S, Borvak J, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 1997;15:637-640.
155. Kenanova V, Olafsen T, Crow DM, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 2005;65:622-631.
156. Kenanova V, Olafsen T, Williams LE, et al. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res 2007;67:718-726.
157. Ferl GZ, Kenanova V, Wu AM, DiStefano JJ 3rd. A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther 2006;5:1550-1558.
158. Wu AM, Tan GJ, Sherman MA, et al. Multimerization of a chimeric anti-CD20 singlechain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng 2001;14:1025-1033.
159. Abuchowski A, McCoy JR, Palczuk NC, vanEs T, Davis FF. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977;252:3582-3586.
160. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001;12:195-202.
161. Wilkinson I, Jackson CJ, Lang GM, Holford-Strevens V, Sehon AH. Tolerogenic polyethylene glycol derivatives of xenogeneic monoclonal immunoglobulins. Immunol Lett 1987;15:17-22.
162. Takashina K, Kitamura K, Yamaguchi T, Noguchi A, Tsurumi H, Takahashi T. Comparative pharmacokinetic properties of murine monoclonal antibody A7 modified with neocarzinostatin, dextran and polyethylene glycol. Jpn J Cancer Res 1991; 82:1145-1150.
163. Lee LS, Conover C, Shi C, Whitlow M, Filpula D. Prolonged circulating lives of singlechain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Bioconjug Chem 1999;10:973-981.
164. Li L, Yazaki PJ, Anderson AL, et al. Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. Bioconjug Chem 2006;17:68-76.
165. Molineux G. Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev 2002;28 Suppl A: 13-16.
166. Natarajan A, Xiong C, Albrecht H, DeNardo GL, DeNardo SJ. Characterization of sitespecific ScFv PEGylation for tumor-targeting pharmaceuticals. Bioconjug Chem 2005;16:113-121.
167. Yang K, Basu A, Wang M, et al. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng 2003;16:761-770.
168. Xiong CY, Natarajan A, Shi XB, Denardo GL, Denardo SJ. Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding. Protein Eng Des Sel 2006;19:359-367.
169. Albrecht H, Denardo GL, Denardo SJ. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility. J Immunol Methods 2006;310:100-116.
170. Kragh-Hansen U, Chuang VT, Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 2002;25:695-704.
171. Chuang VT, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 2002;19:569-577.
172. Smith BJ, Popplewell A, Athwal D, et al. Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug Chem 2001;12:750-756.
173. Yazaki PJ, Kassa T, CheungCW, et al. Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl Med Biol 2008;35:151-158.
174. Tijink BM, Laeremans T, Budde M, et al. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther 2008;7:2288-2297.
175. Dennis MS, Zhang M, Meng YG, et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 2002;277:35035-35043.
176. Dennis MS, Jin H, Dugger D, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 2007;67:254-261.
177. Nguyen A, Reyes AE, 2nd Zhang M, et al. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel 2006;19:291-297.